$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The human gut microbiome includes a diverse array of microbial species, including beneficial commensals and opportunistic pathogens, which interact to support host health. These microbes contribute to essential functions such as nutrient metabolism, immune system modulation, and maintenance of intestinal barrier integrity. However, disruptions to this equilibrium—referred to as dysbiosis—can have widespread physiological consequences.
Dysbiosis is often characterized by reduced microbial diversity and an imbalance in the relative abundance of major bacterial phyla. Diet significantly influences these microbial dynamics. Diets high in dietary fiber promote the growth of Bacteroidota, which are associated with anti-inflammatory functions and the production of short-chain fatty acids (SCFAs) such as butyrate. These metabolites support colonic health and help regulate immune responses. Conversely, diets rich in fats tend to favor Bacillota, a phylum linked with enhanced energy harvest from food, which may contribute to adiposity.
The use of broad-spectrum antibiotics can exacerbate dysbiosis by depleting commensal bacteria, thus enabling opportunistic pathogens such as Clostridioides difficile to proliferate. This pathogen can outcompete residual flora and secrete toxins that further damage the intestinal environment, compounding the disruption.
Dysbiosis is implicated in compromising the epithelial barrier of the intestine. Tight junction proteins between epithelial cells become degraded, leading to increased intestinal permeability, commonly referred to as "leaky gut." This permits translocation of bacterial components, notably lipopolysaccharides (LPS), into systemic circulation. Circulating LPS acts as an endotoxin, activating immune cells and adipocytes to secrete pro-inflammatory cytokines and promoting lipid accumulation in arterial walls, thereby increasing the risk for metabolic syndromes, including obesity and atherosclerosis.
Long-term microbial imbalance is associated with heightened susceptibility to chronic inflammatory diseases. Inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis, has been linked to persistent dysbiosis, wherein altered microbial composition perpetuates mucosal inflammation and immune dysregulation. Understanding these relationships is critical for developing microbiome-targeted therapies.
